Back to Awarded Treatment Trials
Awarded Trial: 02T-270
Grant ID
02T-270
Illness
Schizophrenia
Primary Drug/Intervention
Buspirone
Primary Dosage
30mg b.i.d.
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Meltzer
Sample Size
74
Duration of Study Period for Each Subject
6 months
Outcome Measurements
PANSS, BPRS, Extrapyramidal side effects, quality of life, cognitive battery
Results
Seventy-four patients were enrolled in the study. At three months, buspirone treatment was associated with significant improvement on the digital symbol substitution test, which measures attention and vigilance. This effect was not present at earlier time points or at 6 months. There was no significant effect on other cognitive variables or on symptom ratings.
Publication
Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007 Sep;95(1-3):158-68.
Link
http://www.ncbi.nlm.nih.gov/pubmed/17628435
PI Name
Herbert Meltzer
Degree
MD
Center
Vanderbilt University Medical Center
Institution
Vanderbilt University School of Medicine
Address
1601 23rd Ave S, Suite 306
City or Town
Nashville
State or Province
TN
Zip or Postal Code
37212
Country
USA
Email Address
herbert.meltzer@vanderbilt.edu